Dr Alexander Chernov| neuro-oncology | Best Researcher Award 
DR at Institute of Experimental Medicine🎓
Dr. Alexander Nikolaevich Chernov is a PhD and Senior Researcher at the World-Class Research Centre “Center for Personalized Medicine” at the Institute of Experimental Medicine, Saint Petersburg, Russia 🧬. With an impressive portfolio of over 80 scientific papers, six patents, and ongoing collaborations with international institutions, Dr. Chernov has made significant contributions in the fields of neuroimmunooncology, glioblastoma research, and the study of nerve growth factors. In 2021, he defended his PhD thesis on the effects of nerve growth factor and immune peptides on brain tumor cells, and in 2022-2023, he completed a postdoctoral fellowship at Ben-Gurion University, Israel 🇮🇱.
Professional Profile
Education 🎓
Dr. Chernov holds a PhD with expertise in neurobiology, focusing on brain tumors and chemotherapy. He has a solid foundation in biochemistry, serving as an assistant professor at Saint Petersburg State Pediatric Medical University 🎓.
Work Experience 🏢
Dr. Chernov’s extensive research includes working as a senior researcher at multiple prestigious institutions in Russia, including the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology. He has also been involved in numerous consultancy and industry projects across nine different sectors.
Awards and Honors 🏆
Dr. Chernov has earned recognition for his exceptional work in brain tumor research, including the nomination for the Best Researcher Award for his article on glioblastoma sensitivity to antimicrobial peptides.
👨🏫 Teaching & Memberships🌍
Dr. Chernov is a dedicated educator, currently teaching biochemistry at Saint Petersburg State Pediatric Medical University. He is a member of the Belarusian Society of Physiologists, contributing to his international scientific community .
Research Focus 🔍
His main research areas include glioblastoma, nerve growth factors, chemotherapy, and antimicrobial peptides such as LL-37 and PG-1 🧠. Dr. Chernov’s groundbreaking work has shown how these peptides, in combination with chemotherapy drugs, can predict overall survival in patients with glioblastoma. His research has also demonstrated the effects of these combinations on the inhibition of glioma cell clonogenicity and migration.
Publications :
- “Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors”
- Medicinal Chemistry, 2012
- “Fourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier”
- “Biological activity of silver-doped DLC films”
- Diamond and Related Materials, 2009
- “Analysis of the Spectrum of ACE2 Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome”
- Frontiers in Genetics, 2020
- “Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients”
- Frontiers in Immunology, 2021
- “The phenomenon of multidrug resistance in glioblastomas”
- Hematology/Oncology and Stem Cell Therapy, 2021
- “Genetic risk factors for the development of COVID-19 coronavirus infection”
- Russian Journal of Genetics, 2021
- “Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients”
- “Pathophysiological mechanisms of autism in children”
- Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2020
- “Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration”